myotonic dystrophy Type 1

steps race jump stairs climb

Biotech

PepGen gains a little pep in its step as FDA clears trial hold

A phase 1 study for PepGen’s myotonic dystrophy therapy has been cleared for launch in the U.S. after a five-month FDA clinical hold.

Annalee Armstrong Oct 12, 2023 7:00am

Letter opening FDA clinical hold

Awaiting FDA letter, PepGen oligonucleotide no closer to clinic

Jun 14, 2023 9:05am

Stop sign

FDA blocks PepGen's attempt to get 2nd oligonucleotide to clinic

May 31, 2023 8:11am

Photo of a chain being held together by a piece of rope

Avidity says FDA has 'eased' partial hold on lead asset

May 17, 2023 11:16am

Vertex

Vertex pays Entrada $224M for preclinical rare disease drug

Dec 8, 2022 9:06am